Is having more preapproval data the best way to assure drug safety?
View/ Open
Is having more preapproval data.pdf (92.25Kb)
Access Status
Full text of the requested work is not available in DASH at this time ("restricted access"). For more information on restricted deposits, see our FAQ.Author
Published Version
https://doi.org/10.1377/hlthaff.27.5.w371Metadata
Show full item recordCitation
Garber, Alan M. 2008. Is having more preapproval data the best way to assure drug safety? Health Affairs 27, 5:371-373Abstract
An intensified focus on drug safety often leads to demands for more data collection prior to drug approval. Other approaches can be used, such as enhanced postmarketing surveillance. Many drug benefits and adverse effects are unlikely to become apparent before wide distribution among diverse patients. The best balance of pre- and postapproval data collection may vary by drug. The consequences of alternative strategies are complex and not always immediately apparent, so formal modeling offers the best approach to determine which strategy is optimal in each case.Citable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11577991
Collections
- HCA Scholarly Articles [622]
Contact administrator regarding this item (to report mistakes or request changes)